课题基金 / 基金详情

The use of genomics-driven drug repurposing to prevent cisplatin-induced ototoxicity in pediatric oncology patients

The use of genomics-driven drug repurposing to prevent cisplatin-induced ototoxicity in pediatric oncology patients
使用基因组学驱动的药物再利用来预防儿科肿瘤患者顺铂引起的耳毒性
批准号：
441861
负责人：
Drogemoller Britt I
金额：
$7.65万
依托单位：
University of Manitoba
依托单位国家：
加拿大
项目类别：
Operating Grants
财政年份：
2021
资助国家：
加拿大
项目状态：
已结题
起止时间：
2021-02-01 至 2024-02-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=441861&lang=en
关键词：
Cisplatin-Induced Ototoxicity Drug Repurposing Pediatric Oncology Pharmacogenomics Precision Medicine Single Cell Sequencing

项目摘要

项目成果

Drogemoller Britt I的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cisplatin is a chemotherapeutic which is used in the treatment of several cancers. Unfortunately, this cancer treatment also causes severe and debilitating adverse drug reactions such as hearing loss, which occurs in approximately 60% of children receivin
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioinformatic investigation of previously neglected regions of the genome and their association with age-related hearing loss
  • 批准号：
    481299
  • 项目类别：
    Operating Grants
  • 资助金额：
    $5.1万
  • 财政年份：
    2022
  • 负责人：
    Drogemoller Britt I
  • 依托单位：
    University of Manitoba
Canada Research Chairs - Tier 2
  • 批准号：
    424811
  • 项目类别：
  • 资助金额：
    $43.71万
  • 财政年份：
    2019
  • 负责人：
    Drogemoller Britt I
  • 依托单位：
    University of Manitoba
Identification of the genetic variants involved in the development of severe adverse drug reactions in cancer patients treated with cisplatin
  • 批准号：
    361734
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $9.83万
  • 财政年份：
    2016
  • 负责人：
    Drogemoller Britt I
  • 依托单位：
    University of British Columbia
海外基金